JUST IN: A groundbreaking beef-flavoured daily pill developed by US biotech startup Loyal promises to extend the healthy lifespan of senior dogs and is expected to become available as early as late 2026.
The pill, known as LOY-002, targets age-related metabolic changes in dogs aged 10 years and older (weighing at least 14 lbs / 6.3 kg). It aims to reduce frailty, improve overall health, and potentially add at least one extra year — and in some cases more — of quality time with beloved pets.
What Is LOY-002 and How Does It Work?
Loyal’s innovative drug works by addressing metabolic dysfunction that accelerates ageing in dogs. It mimics some benefits of caloric restriction without requiring any change in diet, helping to lower elevated levels of the hormone IGF-1, which is linked to faster ageing and age-related diseases in senior dogs.
Company founder and CEO Celine Halioua has emphasised: “We’re not making immortal dogs… The way the drug extends lifespan, we hypothesise, is by extending health and thus shortening the rate of ageing.”
The pill is designed as a tasty beef-flavoured chew that senior dogs are likely to accept easily as a daily treat.
Current Progress and FDA Milestones
Loyal has already cleared two of the three major requirements for conditional FDA approval:
- Reasonable Expectation of Effectiveness (RXE)
- Target Animal Safety (TAS)
Only the manufacturing and technical requirements remain. If all goes as planned, veterinarians could start prescribing LOY-002 by the end of 2026, making it the first FDA-approved drug specifically intended to extend lifespan in any species.
A large-scale clinical trial called the STAY study is currently underway, involving over 1,000 dogs across dozens of veterinary clinics in the US. Half the dogs receive the real beef-flavoured pill, while the other half get a placebo.
Why This Matters for Pet Parents and the NRI Community
For millions of Indian families and NRIs across the USA, UK, Gulf countries, Canada, Australia, and beyond, dogs are cherished family members. Extending their healthy years means more time for walks, play, and companionship — especially important for those living abroad who often treat pets like children.
The development also excites the growing pet care industry among the Indian diaspora, where premium pet products and veterinary care are becoming increasingly popular.
Important Note: This is not an immortality drug. Results are expected to vary, and the pill is intended only for senior dogs meeting the age and weight criteria. Loyal is also developing other longevity treatments, including options tailored for large and giant breeds that typically have shorter lifespans.
What Pet Owners Should Know
- Availability: Expected through veterinarians (prescription-only) in late 2026 or early 2027, subject to final FDA approval.
- Cost and Access: Pricing details have not yet been announced.
- Advice: Continue regular vet check-ups, balanced diet, exercise, and routine care. This pill, if approved, would be an additional tool — not a replacement for good pet parenting.
The pet longevity sector is booming, with Loyal having raised over $250 million from investors to advance its research. Success with dogs could eventually pave the way for insights into human ageing as well.
